Alternative bladder cancer treatment emerges amid worldwide shortage of standard of care BCG

An on-going, worldwide shortage of bacillus Calmette-Guérin (BCG) means that many patients with a common and serious type of bladder cancer have limited access to this effective standard of care treatment. But, for the first time in almost 50 years, there appears to be a viable treatment alternative. A new study from the University of Iowa finds that a safe, […]

Nivolumab study supports use of immune checkpoint inhibitors in advanced skin cancer

Researchers report that patients with advanced cutaneous squamous cell carcinoma, a skin cancer and one of the most frequent malignancies worldwide, benefit from treatment with the immune checkpoint inhibitor nivolumab. The findings were published on Oct. 24, 2022 in Cancer. “This is the first study to investigate nivolumab in this patient population, and it provides further evidence supporting the use […]

Leading radiotherapy researchers identify research priorities to improve outcomes for cancer patients

The NCRI Radiotherapy (CTRad) Group, a world-leading radiotherapy research group, has published its strategic priorities in radiotherapy research to address challenges in the field. The group has identified four strategic priorities it believes need to be addressed by the community to improve outcomes for patients: Translating novel discoveries to and from the clinic Evaluating and optimal implementation of new radiotherapy […]

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago […]

Improved treatment emerges for mantle cell lymphoma

Addition of ibrutinib to standard chemotherapy for patients over 65 with previously untreated mantle cell lymphoma (MCL) has led to significantly improved progression-free survival, researchers reported on June 2, 2022 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were published simultaneously in the New England Journal of Medicine. “The majority of mantle cell lymphoma patients who are […]